Synonym
BRN-0308518; BRN0308518; BRN 0308518; Sulfaphenazole; Firmazolo; Inamil
IUPAC/Chemical Name
4-amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide
InChi Key
QWCJHSGMANYXCW-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2
SMILES Code
O=S(NC1=CC=NN1C2=CC=CC=C2)(C3=CC=C(N)C=C3)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
314.36
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Shimamoto N. [A pathophysiological role of cytochrome p450 involved in production of reactive oxygen species]. Yakugaku Zasshi. 2013;133(4):435-50. Review. Japanese. PubMed PMID: 23546588.
2: Emoto C, Yoda N, Uno Y, Iwasaki K, Umehara K, Kashiyama E, Yamazaki H. Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles. Curr Drug Metab. 2013 Feb;14(2):239-52. Review. PubMed PMID: 22963393.
3: Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16. doi: 10.1007/s13318-011-0024-2. Epub 2011 Feb 19. Review. PubMed PMID: 21336516.
4: van Beusekom CD, Schipper L, Fink-Gremmels J. Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs. J Vet Pharmacol Ther. 2010 Dec;33(6):519-27. doi: 10.1111/j.1365-2885.2010.01199.x. Review. PubMed PMID: 21062303.
5: Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia. 1995;36 Suppl 5:S8-13. Review. PubMed PMID: 8806399.
6: Van Duijkeren E, Vulto AG, Van Miert AS. Trimethoprim/sulfonamide combinations in the horse: a review. J Vet Pharmacol Ther. 1994 Feb;17(1):64-73. Review. PubMed PMID: 8196097.
7: Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol. 1992 Dec 1;44(11):2089-98. Review. PubMed PMID: 1472073.
8: Vree TB, Hekster YA, Anderson PG. Contribution of the human kidney to the metabolic clearance of drugs. Ann Pharmacother. 1992 Nov;26(11):1421-8. Review. PubMed PMID: 1477449.
9: Kutt H, Penry JK. Usefulness of blood levels of antiepileptic drugs. Arch Neurol. 1974 Nov;31(5):283-8. Review. PubMed PMID: 4138035.
10: Krieglstein J. [Plasma protein binding of drugs]. Klin Wochenschr. 1969 Nov 1;47(21):1125-30. Review. German. PubMed PMID: 4909984.
11: GELINOV Kh. [SULFONAMIDES THEN AND NOW]. Suvr Med (Sofiia). 1963;14:55-64. Review. Bulgarian. PubMed PMID: 14103145.
